Anti-myeloma activity of pamidronate in vivo

Madhav V. Dhodapkar, Joginder Singh, Jayesh Mehta, Athanasios Fassas, K. R. Desikan, Martin Perlman, Nikhil C. Munshi, Bart Barlogie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

90 Scopus citations


Two patients with progressive myeloma were treated with pamidronate disodium every 2-4 weeks. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labelling index (PCLI), together with durable (≥20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient and >50% reduction in Ig levels and bone marrow plasmacytosis in the second. This, to our knowledge, is the first report of an anti-myeloma effect of bisphosphonates in humans and provides evidence that a therapeutic intervention largely directed at the myeloma microenvironment may alter the natural history of the disease.

Original languageEnglish (US)
Pages (from-to)530-532
Number of pages3
JournalBritish Journal of Haematology
Issue number2
StatePublished - 1998


  • Bisphosphonates
  • Bone
  • Growth
  • Myeloma
  • Pamidronate

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Anti-myeloma activity of pamidronate in vivo'. Together they form a unique fingerprint.

Cite this